CompletedPhase 2

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

United States30 participantsStarted 2005-09

Plain-language summary

The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Stable congestive heart failure * Impaired renal function * Taking oral loop diuretic Exclusion Criteria: * Acutely decompensated (unstable) and end stage heart failure * Diuretics other than loop diuretics * Pregnant or nursing * Inability to follow instructions * Participation in another clinical trial within past 30 days

What they're measuring

Comparison of KW-3902IV alone or with loop diuretic on renal function.

Trial details

NCT IDNCT00159614

SponsorNovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Heart Failure, Congestive trials